Fate Therapeutics (FATE) Earnings Date, Estimates & Call Transcripts $1.35 +0.02 (+1.50%) As of 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Fate Therapeutics Earnings Summary Upcoming Earnings DateMay. 8Before Market OpensEstimatedConsensus EPS (Mar. 5) -$0.44 Actual EPS (Mar. 5) -$0.31 Beat By $0.13 Actual Revenue (Mar. 5) $1.86MFate Therapeutics issued Q4 2024 earnings on March 5, 2025, reporting an EPS of -$0.31, which topped the consensus estimate of -$0.44 by $0.13. Quarterly revenue was reported to be $1.86 million, above analysts' expectations of $1.57 million. With a trailing EPS of -$1.64, Fate Therapeutics' earnings are expected to decrease next year, from ($1.63) to ($1.69) per share. Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Press Release (8-K) Annual Report (10-K)FATE Upcoming EarningsFate Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get Fate Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataFATE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.FATE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Fate Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.46-$0.42-$0.45Q2 20253-$0.48-$0.43-$0.46Q3 20253-$0.49-$0.45-$0.48Q4 20253-$0.50-$0.33-$0.44FY 202512($1.93)($1.63)($1.83) Fate Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/8/2025(Estimated)-------3/5/2025Q4 2024-$0.44-$0.31+$0.13-$0.44$1.57M$1.86M11/12/2024--$0.42-$0.40+$0.02-$0.40$0.88M$3.07M8/13/2024--$0.47-$0.33+$0.14-$0.33$1.47M$6.77M5/9/2024Q1 2024-$0.47-$0.47--$0.47$0.80M$1.93M2/26/2024Q4 2023-$0.57-$0.45+$0.12-$0.45$0.85M$1.68M11/8/2023Q3 2023-$0.59-$0.46+$0.13-$0.46$0.99M$1.94M8/8/2023Q2 2023-$0.58-$0.54+$0.04-$0.54$5.41M$0.93M5/3/2023Q1 2023-$0.55-$0.19+$0.36-$0.19$33.53M$58.98M Fate Therapeutics Earnings - Frequently Asked Questions When is Fate Therapeutics's earnings date? Fate Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based off last year's report dates. Learn more on FATE's earnings history. Did Fate Therapeutics beat their earnings estimates last quarter? In the previous quarter, Fate Therapeutics (NASDAQ:FATE) reported ($0.31) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.44) by $0.13. Learn more on analysts' earnings estimate vs. FATE's actual earnings. How much revenue does Fate Therapeutics generate each year? Fate Therapeutics (NASDAQ:FATE) has a recorded annual revenue of $13.63 million. How much profit does Fate Therapeutics generate each year? Fate Therapeutics (NASDAQ:FATE) has a recorded net income of -$160.93 million. FATE has generated -$1.64 earnings per share over the last four quarters. What is Fate Therapeutics's EPS forecast for next year? Fate Therapeutics's earnings are expected to decrease from ($1.63) per share to ($1.69) per share in the next year. More Earnings Resources from MarketBeat Related Companies PHAR Earnings Results VALN Earnings Results ORGO Earnings Results CRMD Earnings Results UPB Earnings Results BCYC Earnings Results IMTX Earnings Results PRTA Earnings Results KURA Earnings Results SION Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step InWhy It May Be Time to Buy CrowdStrike Stock Heading Into EarningsCan IBM’s Q1 Earnings Spark a Breakout for the Stock? This page (NASDAQ:FATE) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
